{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:25:23Z","timestamp":1744064723171},"reference-count":14,"publisher":"SAABRON PRESS","issue":"2-3","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Hematol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy being employed in currently enrolling clinical trials for patients with multiple myeloma and highlights how high-risk myeloma patients may be assigned to maintenance strategies incongruent with current US guidelines.<\/jats:p>","DOI":"10.1007\/s44228-023-00044-8","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T09:02:54Z","timestamp":1683104574000},"page":"170-176","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma"],"prefix":"10.46989","volume":"5","author":[{"given":"Syed Maaz","family":"Tariq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec","family":"Britt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26435","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"issue":"9","key":"44_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321.","journal-title":"Leukemia"},{"issue":"4","key":"44_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44.","journal-title":"Blood Cancer J"},{"issue":"14","key":"44_CR3","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood-2008-07-170746","volume":"113","author":"M Rotta","year":"2009","unstructured":"Rotta M, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113(14):3383\u201391.","journal-title":"Blood"},{"issue":"29","key":"44_CR4","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389.","journal-title":"J Clin Oncol"},{"issue":"19","key":"44_CR5","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"44_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57\u201373.","journal-title":"Lancet Oncol"},{"issue":"15_Suppl","key":"44_CR7","first-page":"8004","volume":"39","author":"P Moreau","year":"2021","unstructured":"Moreau P, Sonneveld P, F.T.C.S. Investigators. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. Blood. 2021;39(15_Suppl):8004\u20138004.","journal-title":"Blood"},{"issue":"7","key":"44_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","volume":"33","author":"SK Kumar","year":"2019","unstructured":"Kumar SK, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019;33(7):1736\u201346.","journal-title":"Leukemia"},{"key":"44_CR9","unstructured":"Clinic, M. MSMART Guidelines. 2022. https:\/\/www.msmart.org\/mm-treatment-guidelines. Accessed 25 Jul 2022"},{"issue":"15","key":"44_CR10","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","volume":"37","author":"F Gay","year":"2019","unstructured":"Gay F, et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. J Clin Oncol. 2019;37(15):8002\u20138002.","journal-title":"J Clin Oncol"},{"issue":"5","key":"44_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella M, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer. 2019;125(5):750\u201360.","journal-title":"Cancer"},{"key":"44_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00665-7","author":"ERS Cliff","year":"2022","unstructured":"Cliff ERS, Rehman-Mohyuddin G. Overall survival as a primary end point in multiple myeloma trials. Nat Rev Clin Oncol. 2022. https:\/\/doi.org\/10.1038\/s41571-022-00665-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"44_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ajh.26166","volume":"96","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, et al. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review. Am J Hematol. 2021;96(6):690\u20137.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"44_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2021-152648","volume":"138","author":"A Fleischer","year":"2021","unstructured":"Fleischer A, et al. Is PFS the right endpoint to assess outcome of maintenance studies in multiple myeloma? Results of a patient survey highlight quality-of-life as an equally important outcome measure. Blood. 2021;138(Supplement 1):836\u2013836.","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-023-00044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44228-023-00044-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-023-00044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:21:50Z","timestamp":1694424110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44228-023-00044-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":14,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s44228-023-00044-8","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests other than the following for DS: DS reports consulting for Janssen, SkylineDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene, AG reports consulting for EUSA Pharma and Seattle Genetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}